177 related articles for article (PubMed ID: 25399645)
21. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
22. The synergy between combinatorial chemistry and high-throughput screening.
Diller DJ
Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
[TBL] [Abstract][Full Text] [Related]
23. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
Chuaqui C; Deng Z; Singh J
J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
[TBL] [Abstract][Full Text] [Related]
24. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action.
Navratilova I; Macdonald G; Robinson C; Hughes S; Mathias J; Phillips C; Cook A
J Biomol Screen; 2012 Feb; 17(2):183-93. PubMed ID: 22068706
[TBL] [Abstract][Full Text] [Related]
25. Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38α MAP Kinase Type-I/II/III Inhibitors.
You W; Chang CA
J Chem Inf Model; 2018 May; 58(5):968-981. PubMed ID: 29620886
[TBL] [Abstract][Full Text] [Related]
26. Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery.
Slon-Usakiewicz JJ; Dai JR; Ng W; Foster JE; Deretey E; Toledo-Sherman L; Redden PR; Pasternak A; Reid N
Anal Chem; 2005 Mar; 77(5):1268-74. PubMed ID: 15732906
[TBL] [Abstract][Full Text] [Related]
27. Allosteric Effect of Adenosine Triphosphate on Peptide Recognition by 3'5'-Cyclic Adenosine Monophosphate Dependent Protein Kinase Catalytic Subunits.
Kivi R; Solovjova K; Haljasorg T; Arukuusk P; Järv J
Protein J; 2016 Dec; 35(6):459-466. PubMed ID: 27848106
[TBL] [Abstract][Full Text] [Related]
28. Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
Parker LJ; Taruya S; Tsuganezawa K; Ogawa N; Mikuni J; Honda K; Tomabechi Y; Handa N; Shirouzu M; Yokoyama S; Tanaka A
Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):392-404. PubMed ID: 24531473
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
30. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
31. Universal and Quantitative Method To Evaluate Inhibitor Potency for Cysteinome Proteins Using a Nonspecific Activity-Based Protein Profiling Probe.
Sameshima T; Tanaka Y; Miyahisa I
Biochemistry; 2017 Jun; 56(23):2921-2927. PubMed ID: 28520393
[TBL] [Abstract][Full Text] [Related]
32. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
33. Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.
Wilson BA; Alam MS; Guszczynski T; Jakob M; Shenoy SR; Mitchell CA; Goncharova EI; Evans JR; Wipf P; Liu G; Ashwell JD; O'Keefe BR
J Biomol Screen; 2016 Mar; 21(3):277-89. PubMed ID: 26538432
[TBL] [Abstract][Full Text] [Related]
34. Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors.
Vanderpool D; Grimshaw CE; Lawson JD; Ermolieff J
Anal Biochem; 2015 Mar; 473():46-52. PubMed ID: 25535956
[TBL] [Abstract][Full Text] [Related]
35. Rapid identification of ligand-binding sites by using an assignment-free NMR approach.
Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H
J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460
[TBL] [Abstract][Full Text] [Related]
36. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
37. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
38. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
39. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
40. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
